Program
betamethasone dipropionate
Also written as “LEO 90100”, “MC2-01 cream” and “Calcipotriol plus betamethasone dipropionate (LEO80185 gel)”.
Its studies are mostly in Psoriasis · Skin and Connective Tissue Diseases · Dermatitis, Atopic, led by 5 companies.
Drug pageBetamethasone dipropionate: every studyMany companies study it; this page follows only the 26 they lead. All 42 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| LEO Pharmaits history only | 180 open or running | phase 4since Nov 3, 2005 | Sep 15, 2005 | none ahead |
| MC2 Therapeuticsits history only | 50 open or running | phase 3since Oct 9, 2017 | Oct 9, 2017 | none ahead |
| Glenmark Pharmaceuticals Ltd. Indiaits history only | 10 open or running | phase 3since Nov 1, 2017 | Nov 1, 2017 | none ahead |
| Huadong Medicine | 10 open or running | phase 3since Dec 11, 2025 | Dec 11, 2025 | none ahead |
| Primus Pharmaceuticalsits history only | 10 open or running | phase 4since Apr 13, 2016 | Apr 13, 2016 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Huadong Medicine only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 11, 2025First study: phase 3 study in Plaque PsoriasisFirst studyNCT07357831 · 539 enrolled · China
TargetBeta
“Glucocorticoid receptor agonist”ChEMBL 37, by rule
Other programs on NR3C1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Dexamethasonerule | AbbVie | phase 4 | 174 |
| Budesoniderule | AstraZeneca | phase 4 | 167 |
| fluticasone furoaterule | GlaxoSmithKline | phase 4 | 97 |
| Prednisonerule | Johnson & Johnson | phase 4 | 65 |
| Beclomethasonerule | Chiesi Farmaceutici | phase 4 | 46 |
| Prednisolonerule | Sanofi | phase 4 | 34 |
| Methylprednisolonerule | Pfizer | phase 4 | 23 |
| dexamethasone phosphaterule | eyegate-pharmaceuticals-inc | phase 4 | 21 |
| Betamethasonerule | LEO Pharma | phase 4 | 9 |
| Triamcinolonerule | research-insight-llc | phase 4 | 5 |
| relacorilantrule | Corcept Therapeutics | phase 3 | 22 |
| Triamcinolone Acetoniderule | clearside-biomedical-inc | phase 3 | 20 |
Studies
The one study Huadong Medicine leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07357831Plaque Psoriasis · China | 3 | Completed | Aug 6, 2026 | 539 |
How it is read
Names in the registry
- “LEO 90100”, 7 entries
- “MC2-01 cream”, 4 entries
- “Calcipotriol plus betamethasone dipropionate (LEO80185 gel)”, 3 entries
- “MC2-01 Cream”, 2 entries
- “Calcipotriene plus betamethasone dipropionate ointment”, 1 entry
Conditions, from the studies’ own filings
- Psoriasis, 24 studies
- Skin and Connective Tissue Diseases, 1 study
- Dermatitis, Atopic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.